Ultragenyx Pharmaceutical Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated February 16, 2017, reports the financial results for Ultragenyx Pharmaceutical Inc. for the three months ended December 31, 2016, and the full year ended December 31, 2016. The detailed financial data is contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the attached press release (Exhibit 99.1) but are not present in the body of this 8-K document.
Material Changes
The filing text does not provide specific details regarding material changes versus prior periods. It serves solely as a notification that the results for the specified periods have been announced.
Guidance, Outlook, and Risks
The filing text does not include management commentary, guidance, outlook, risks, contingencies, or unusual items. The document explicitly states that the information in the press release is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate as reported in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm the date of the report (February 16, 2017) aligns with the most recent available data.